title: ¹⁸F-FDG-PET/CT in staging, restaging, and treatment response assessment of male breast cancer.
abstract: OBJECTIVE
  Male breast cancer (BC) is a rare disease, with patterns different from those found in women. Most tumors are detected at more advanced stages than in women. The aim of this study was to analyze the performance of [18F]fluorodeoxyglucose positron emission tomography/computed tomography ((18)F-FDG-PET/CT) in staging, restaging, and therapy response assessment.
  
  
  METHODS
  We performed a systematic analysis in the database of Saint-Louis Hospital to identify male patients with BC referred for PET/CT. (18)F-FDG-PET/CT findings considered suspicious for malignancy were compared to biopsy results, further work-up and/or patient follow-up of at least 6 months. Performances of (18)F-FDG-PET/CT were compared to that of conventional imaging (CI) using the McNemar test. The impact of PET/CT on management was evaluated.
  
  
  RESULTS
  During 6 consecutive years, among 12,692 (18)F-FDG-PET/CT oncology studies, 30 were performed in 15 men with BC: 7 examinations for initial staging, 11 for restaging, and 12 for response assessment. Tumors profile was ER+ and one had HER2 overexpression. PET/CT sensitivity, specificity, positive predictive value, negative predictive value and accuracy to detect distant metastases were 100%, 67%, 86%, 100% and 89%, respectively. PET/CT was more informative than CI in 40% of studies (p=0.03; 95% confidence interval: 3.26 - 40%). Findings from (18)F-FDG-PET/CT led to modification in the planned treatment in 13/30 cases (43%).
  
  
  CONCLUSIONS
  Although all the tumors were ER+, primary lesions and metastases were diagnosed with high sensitivity. (18)F-FDG-PET/CT seems to be a powerful imaging method to perform staging, restaging and treatment response assessment in male patients with BC.
authors.affiliation: Department of Nuclear Medicine, Saint-Louis Hospital, Paris, France; Doctoral School of Biology and Biotechnology, University Institute of Hematology, University of Paris VII, Paris, France. Electronic address: dgroheux@yahoo.fr.
authors.forename: David
authors.initials: D
authors.lastname: Groheux
authors.affiliation: Department of Nuclear Medicine, Haut-Lévêque Hospital, CHU Bordeaux, University Bordeaux-Segalen, Bordeaux, France.
authors.forename: Elif
authors.initials: E
authors.lastname: Hindié
authors.affiliation: Breast Diseases Unit and Department of Medical Oncology, Saint-Louis Hospital, Paris, France; Centre for Therapeutic Innovation, Saint-Louis Hospital, Paris, France.
authors.forename: Michel
authors.initials: M
authors.lastname: Marty
authors.affiliation: Breast Diseases Unit and Department of Medical Oncology, Saint-Louis Hospital, Paris, France.
authors.forename: Marc
authors.initials: M
authors.lastname: Espié
authors.affiliation: Department of Nuclear Medicine, Santa Maria della Misericordia, Rovigo Hospital, Rovigo, Italy.
authors.forename: Domenico
authors.initials: D
authors.lastname: Rubello
authors.affiliation: Department of Nuclear Medicine, Saint-Louis Hospital, Paris, France; Doctoral School of Biology and Biotechnology, University Institute of Hematology, University of Paris VII, Paris, France.
authors.forename: Laetitia
authors.initials: L
authors.lastname: Vercellino
authors.affiliation: Breast Diseases Unit and Department of Medical Oncology, Saint-Louis Hospital, Paris, France; INSERM U728, University Institute of Hematology, University of Paris VII, Paris, France.
authors.forename: Guilhem
authors.initials: G
authors.lastname: Bousquet
authors.affiliation: Department of Nuclear Medicine, Saint-Louis Hospital, Paris, France.
authors.forename: Jessica
authors.initials: J
authors.lastname: Ohnona
authors.affiliation: Department of Nuclear Medicine, Saint-Louis Hospital, Paris, France.
authors.forename: Marie-Elisabeth
authors.initials: ME
authors.lastname: Toubert
authors.affiliation: Department of Nuclear Medicine, Saint-Louis Hospital, Paris, France; Doctoral School of Biology and Biotechnology, University Institute of Hematology, University of Paris VII, Paris, France.
authors.forename: Pascal
authors.initials: P
authors.lastname: Merlet
authors.affiliation: Breast Diseases Unit and Department of Medical Oncology, Saint-Louis Hospital, Paris, France.
authors.forename: Jean-Louis
authors.initials: JL
authors.lastname: Misset
mesh_terms: D000328:Adult; D000368:Aged; D018567:Breast Neoplasms, Male / Q000000981:diagnostic imaging* / Q000473:pathology / Q000628:therapy; D019788:Fluorodeoxyglucose F18; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D064847:Multimodal Imaging; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D049268:Positron-Emission Tomography; D011237:Predictive Value of Tests; D019275:Radiopharmaceuticals; D012680:Sensitivity and Specificity; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D051598:Whole Body Imaging
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18
keywords: (18)F-FDG-PET/CT; Male breast cancer; Restaging; Staging; Treatment response assessment